JP2015500869A - アモルファス性沈殿タンパク質粒子の調製方法 - Google Patents

アモルファス性沈殿タンパク質粒子の調製方法 Download PDF

Info

Publication number
JP2015500869A
JP2015500869A JP2014548209A JP2014548209A JP2015500869A JP 2015500869 A JP2015500869 A JP 2015500869A JP 2014548209 A JP2014548209 A JP 2014548209A JP 2014548209 A JP2014548209 A JP 2014548209A JP 2015500869 A JP2015500869 A JP 2015500869A
Authority
JP
Japan
Prior art keywords
protein
reconstitution
solution
particles
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014548209A
Other languages
English (en)
Japanese (ja)
Inventor
ボス ヤン
ボス ヤン
ジョン マクロード アンドリュー
ジョン マクロード アンドリュー
ダグラス ムーア バリー
ダグラス ムーア バリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Publication of JP2015500869A publication Critical patent/JP2015500869A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014548209A 2011-12-23 2012-12-24 アモルファス性沈殿タンパク質粒子の調製方法 Withdrawn JP2015500869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1122408.6 2011-12-23
GB201122408A GB201122408D0 (en) 2011-12-23 2011-12-23 Method for preparing dry protein formulations
PCT/GB2012/053265 WO2013093524A2 (en) 2011-12-23 2012-12-24 Method for preparing amorphous precipitated protein particles

Publications (1)

Publication Number Publication Date
JP2015500869A true JP2015500869A (ja) 2015-01-08

Family

ID=45695047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548209A Withdrawn JP2015500869A (ja) 2011-12-23 2012-12-24 アモルファス性沈殿タンパク質粒子の調製方法

Country Status (9)

Country Link
US (1) US20140348852A1 (en:Method)
EP (1) EP2793863B1 (en:Method)
JP (1) JP2015500869A (en:Method)
BR (1) BR112014015357A2 (en:Method)
CA (1) CA2859288A1 (en:Method)
DK (1) DK2793863T3 (en:Method)
GB (1) GB201122408D0 (en:Method)
IN (1) IN2014MN01377A (en:Method)
WO (1) WO2013093524A2 (en:Method)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521232A (ja) * 2018-04-16 2021-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ メグルミン塩を使用して製剤を含むタンパク質を安定化するための方法
JP2022519690A (ja) * 2019-02-05 2022-03-24 リンディー バイオサイエンシーズ，インク． 単離された細胞培養成分、及びそれを液状の細胞培養培地から単離する方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174458B2 (en) * 2007-04-23 2021-11-16 Koligo Therapeutics, Inc. Cell separation apparatus and methods of use
GB201313368D0 (en) * 2013-07-26 2013-09-11 Xstalbio Ltd Novel Reconstitution devices
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
WO2020160323A2 (en) 2019-01-31 2020-08-06 Elektrofi, Inc. Particle formation and morphology
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
CN115844752B (zh) * 2022-11-02 2024-06-28 上海铂舍生物科技有限公司 一种5d超分子胶原蛋白及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521232A (ja) * 2018-04-16 2021-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ メグルミン塩を使用して製剤を含むタンパク質を安定化するための方法
JP2022519690A (ja) * 2019-02-05 2022-03-24 リンディー バイオサイエンシーズ，インク． 単離された細胞培養成分、及びそれを液状の細胞培養培地から単離する方法

Also Published As

Publication number Publication date
GB201122408D0 (en) 2012-02-08
US20140348852A1 (en) 2014-11-27
EP2793863A2 (en) 2014-10-29
WO2013093524A2 (en) 2013-06-27
IN2014MN01377A (en:Method) 2015-04-17
WO2013093524A3 (en) 2013-08-15
DK2793863T3 (en) 2018-11-12
CA2859288A1 (en) 2013-06-27
BR112014015357A2 (pt) 2017-07-11
EP2793863B1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
JP2015500869A (ja) アモルファス性沈殿タンパク質粒子の調製方法
JP6416841B2 (ja) 医薬製剤
CA2781467C (en) Formulations of antibody
JP6084987B2 (ja) セミフッ素化アルカンに基づく安定化タンパク質組成物
JP6429784B2 (ja) 抗体の高濃度液体製剤の製造方法
JP2019506406A (ja) 二重特異性抗体コンストラクトを含む医薬組成物
JP2004532262A (ja) 安定な抗体液体製剤
AU2016200495A1 (en) Concentrated protein formulations and uses thereof
JP6407174B2 (ja) 抗体の配合物および該配合物の使用
JP2010509243A5 (en:Method)
JP6884858B2 (ja) 医薬製剤及びその製造方法
US8372798B2 (en) High-concentration protein formulations and method of manufacture
WO2019064263A1 (en) NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS
Deokar et al. Comparison of strategies in development and manufacturing of low viscosity, ultra-high concentration formulation for IgG1 antibody
US20230279146A1 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
AU2019407063A1 (en) Protein solution formulation containing high concentration of an anti-VEGF antibody
JP7538802B2 (ja) カルベトシン医薬品およびその製造プロセス
CN114423414A (zh) 樟脑磺酸及其与阳离子赋形剂的组合作为高浓缩蛋白质制剂中的降粘剂
US20140308293A1 (en) Reconstitution method for high concentration dry protein formulations
CN117460536A (zh) 多肽制剂
WO2025131987A1 (en) Viscosity reducing excipients and combinations thereof for liquid compositions comprising a protein

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151221

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160705